Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 17, Issue 8, Pages 1106-1113
Publisher
Oxford University Press (OUP)
Online
2015-01-08
DOI
10.1093/neuonc/nou345
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care
- (2014) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-free survival: too much risk, not enough reward?
- (2014) B. M. Alexander et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
- (2013) K. Han et al. NEURO-ONCOLOGY
- Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma
- (2012) Lorenzo Trippa et al. JOURNAL OF CLINICAL ONCOLOGY
- Bayesian Enrichment Strategies for Randomized Discontinuation Trials
- (2011) Lorenzo Trippa et al. BIOMETRICS
- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
- (2011) M.-Y. C. Polley et al. NEURO-ONCOLOGY
- Recurrent High-Grade Glioma
- (2010) Eudocia C. Quant et al. Current Treatment Options in Neurology
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive Clinical Trials: The Promise and the Caution
- (2010) Donald A. Berry JOURNAL OF CLINICAL ONCOLOGY
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
- (2008) Alba A. Brandes et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started